Tempus AI Stock Price, News & Analysis

Tempus AI (NASDAQ: TEM) announced four abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The presentations include:

1. An oral presentation on the impact of AI in clinical trial screening and enrollment.

2. A poster on using circulating tumor DNA (ctDNA) to monitor treatment response in patients treated with tyrosine kinase inhibitors.

3. A poster on comprehensive genomic profiling for targeted therapy in advanced lung cancer patients.

4. A poster on the impact of RAS and BRAFV600E mutations on the tumor immune microenvironment in colorectal cancers.

These presentations showcase Tempus' commitment to leveraging AI and data to advance precision medicine and improve patient outcomes in oncology.

Tempus AI, Inc. (NASDAQ: TEM) has launched the beta version of olivia, an AI-enabled personal health concierge app for patients. This innovative app aims to empower individuals to manage their health data holistically. olivia uses generative AI to provide personalized support, offering features such as:

• Seamless connection with healthcare providers
• Comprehensive patient profile creation
• Appointment preparation assistance
• Health monitoring tools

The app addresses the challenge of managing healthcare data across multiple providers and specialties, offering users a centralized platform to organize and access their health information. Tempus CEO Eric Lefkofsky emphasized that olivia leverages the company's investments in AI and multimodal healthcare data aggregation to benefit patients directly.

Tempus AI (NASDAQ: TEM) has announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX) to enhance BioNTech's next-generation oncology pipeline. The partnership leverages Tempus' large multimodal datasets and computational biology expertise to support BioNTech's research and development efforts in oncology.

Tempus will provide analytical support and access to its real-world multimodal database to help BioNTech generate novel insights into biological mechanisms. This collaboration aims to advance the discovery of new therapies and enhance the development of BioNTech's clinical oncology pipeline. The partnership combines Tempus' real-world data and computational technology with BioNTech's AI capabilities and multi-platform discovery engine to potentially bring innovative therapies to cancer patients.

Tempus AI (NASDAQ: TEM), a leader in AI-driven precision medicine, is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion at 8:30 a.m. ET during the event.

This participation highlights Tempus' commitment to advancing healthcare through technology and AI. The conference provides a platform for Tempus to showcase its innovations and discuss the future of precision medicine with industry leaders and investors.

BerGenBio ASA (OSE: BGBIO) reported solid clinical and financial progress in its Q2 2024 results. Key highlights include:

1. BGBC016 1L NSCLC STK11m study progressing well, with Ph1b enrollment completed and Ph2a sites activated.

2. Collaboration with Tempus AI (Nasdaq: TEM) to accelerate bemcentinib development using genomic AI.

3. Strengthened financial position with NOK 138.9 million from warrant exercise, funding secured into H2 2025.

4. Stable cash use with decreased operating expenses: NOK 90.5 million for H1 2024 vs NOK 120.2 million in H1 2023.

5. Focus on bemcentinib as a potential first-in-class selective AXL inhibitor for STK11 mutated NSCLC and severe respiratory infections.

Personalis (PSNL) and Tempus (TEM) have expanded their commercial collaboration, with Tempus investing $36 million in Personalis. This investment includes exercising warrants to purchase 9.2 million shares at an average price of $2.00 and buying an additional 3.5 million shares at $5.07 each. The expansion follows strong demand for their ultra-sensitive MRD testing in breast and lung cancers, as well as immunotherapy monitoring across solid tumors.

Key points of the expanded collaboration include:

• Tempus accelerating commercialization efforts over the first two years
• Personalis increasing the quantity of patient samples it will accept
• Tempus becoming the exclusive commercial partner for Personalis' MRD product
• Tempus owning approximately 19.3% of Personalis' outstanding common stock after the transaction

Tempus AI (NASDAQ: TEM) announced the publication of a validation study for its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay in npj Precision Oncology. The study validates an investigational test that detects HLA-LOH using data from Tempus' FDA-approved xT CDx assay. The test employs a machine learning model to identify solid tumor patients with allele-specific LOH for specific HLA Class I alleles, potentially benefiting from targeted therapies.

The study demonstrated the test's accuracy in detecting HLA-LOH in clinical samples with ≥40% tumor cells. Collaborating with A2 Biotherapeutics, Tempus analyzed data from an observational clinical trial (NCT04981119), showing the feasibility of identifying and accruing HLA-LOH patients for prospective studies. In 2023, the FDA granted Breakthrough Device Designation for the HLA-LOH assay as a companion diagnostic test, although it's currently not available for clinical use.

Tempus AI, Inc. (NASDAQ: TEM) reported Q2 2024 financial results, showing strong growth and expansion. Key highlights include:

- Revenue increased 25% year-over-year to $166.0 million
- Data licensing revenue growth accelerated to 40% year-over-year
- Expanded into the minimal residual disease (MRD) market
- Established a joint venture with Softbank to enter the Japanese market
- Raised $410.7 million in gross proceeds from IPO
- Net Loss of ($552.2 million), largely due to stock compensation expenses
- Adjusted EBITDA improved to ($31.2 million)
- Full year 2024 revenue guidance of ~$700 million, representing ~32% annual growth

The company continues to make progress in deploying AI technology within healthcare, positioning itself as a leader in precision medicine and patient care.

Tempus AI (NASDAQ: TEM) has launched a new program under its Tempus Next platform to identify care gaps in guideline-directed IHC testing, starting with HER2. The program uses a new RNA-based algorithm integrated into Tempus' xR RNA sequencing assay to predict HER2 positivity in tumor samples. This AI-driven approach aims to surface patients more likely to benefit from confirmatory IHC testing, aligning with clinical guidelines for select metastatic cancers.

The program is being piloted at select sites, where Tempus will notify physicians of patients identified as potentially HER2 positive, enabling them to consider ordering confirmatory IHC tests. This initiative leverages Tempus' genomics, AI applications, and data capabilities to provide real-time, guideline-directed care recommendations to physicians, demonstrating the practical application of AI in improving clinical care as treatment options become more complex.